Similarly, Shen et al. employed the same treatment protocol in their study and observed a decrease in urinary biomarkers, namely VEGF and IL-9, in IC/BPS patients by the end of week 4 [70]. This evidence concerns the gene VEGFA and Bartsocas-Papas syndrome 1.